ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells

Castration-resistant prostate cancer (CRPC) expresses high levels of the anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1, resulting in resistance to apoptosis and association with poor prognosis. Docetaxel, an antimitotic drug that is the first-line treatment strategy for CRPC, is known to provide a...

Descripción completa

Detalles Bibliográficos
Autores principales: Parrondo, Ricardo, de las Pozas, Alicia, Reiner, Teresita, Perez-Stable, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2013
Materias:
Molecular Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775631/
https://www.ncbi.nlm.nih.gov/pubmed/24058878
http://dx.doi.org/10.7717/peerj.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775631/
https://www.ncbi.nlm.nih.gov/pubmed/24058878
http://dx.doi.org/10.7717/peerj.144

Ejemplares similares